Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01763931 · ClinicalTrials.gov registry record · Phase 2
DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01763931 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants.
The verdict
NCT01763931, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what effects digoxin (DIG) may have on human breast cancer tissue.
Interventions
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01763931
The ClinicalTrials.gov registry entry for NCT01763931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Digoxin is the first listed.
NCT01763931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01763931 about?
NCT01763931 is a clinical study titled "DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer". The purpose of this study is to learn what effects digoxin (DIG) may have on human breast cancer tissue.
What is the current status of trial NCT01763931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2013-01. Estimated completion is 2016-04-01.
What interventions are being tested in trial NCT01763931?
The interventions under investigation include: Digoxin (DRUG).
Who is sponsoring clinical trial NCT01763931?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.